Jane Street’s Viridian Therapeutics VRDN Stock Holding History

Jane Street’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.96M	Buy	+151,100	New	+$4.49M	﹤0.01%	4374
2025 Q1	–	Sell	-28,000	Closed	-$537K	–	10718
2024 Q4	$537K	Sell	28,000 -53,600	-66%	-$1.17M	﹤0.01%	6636
2024 Q3	$1.86M	Buy	+81,600	New	+$1.33M	﹤0.01%	4627
2023 Q4	–	Sell	-40,000	Closed	-$614K	–	9873
2023 Q3	$614K	Sell	40,000 -198,300	-83%	-$3.78M	﹤0.01%	5966
2023 Q2	$5.67M	Buy	+238,300	New	+$6.11M	﹤0.01%	2564

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jane Street's VRDN Position: Q1 2026 in Review

Jane Street reduced its Viridian Therapeutics (VRDN) stake by 78% in Q1 2026, selling an estimated $6.5M and leaving 60,815 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #6143.

Jane Street first reported a position in VRDN in Q1 2018 and has held it in 16 quarters since. The position peaked at $8.7M in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

Jane Street held 60,815 shares of Viridian Therapeutics worth $1.19M as of Q1 2026.
Jane Street sold 218,792 Viridian Therapeutics shares in Q1 2026, an estimated $6.5M.
Viridian Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #6143 holding.
Jane Street first reported a position in Viridian Therapeutics in Q1 2018 and has held it in 16 quarters since.
Jane Street's Viridian Therapeutics position peaked at $8.7M in Q4 2025.
225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.